Home » Stocks » PTC Therapeutics

PTC Therapeutics, Inc. (PTCT)

Stock Price: $49.02 USD -0.47 (-0.95%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 3.32B
Revenue (ttm) 311.37M
Net Income (ttm) -431.79M
Shares Out 67.70M
EPS (ttm) -6.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $49.02
Previous Close $49.49
Change ($) -0.47
Change (%) -0.95%
Day's Open 49.60
Day's Range 48.72 - 50.03
Day's Volume 482,078
52-Week Range 30.79 - 59.89

More Stats

Market Cap 3.32B
Enterprise Value 3.16B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 67.70M
Float 62.10M
EPS (basic) -6.91
EPS (diluted) -6.94
FCF / Share -3.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.25M
Short Ratio 7.15
Short % of Float 7.83%
Beta 1.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10.66
PB Ratio 5.61
Revenue 311.37M
Operating Income -372.43M
Net Income -431.79M
Free Cash Flow -230.84M
Net Cash 157.32M
Net Cash / Share 2.32
Gross Margin 12.01%
Operating Margin -119.61%
Profit Margin -138.70%
FCF Margin -74.14%
ROA -16.82%
ROE -81.38%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 5
Overweight 1
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$60.00*
(22.40% upside)
Low
46.0
Current: $49.02
High
86.0
Target: 60.00
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue30726519482.7136.7725.2534.7033.95105
Revenue Growth15.96%36.19%135.04%124.95%45.64%-27.24%2.21%-67.8%-
Gross Profit29525219082.7136.7725.2534.7033.95105
Operating Income-193-96.35-64.29-132-167-99.41-45.40-26.8130.58
Net Income-252-128-79.00-142-170-93.75-48.1813430.91
Shares Outstanding58.8646.5839.1834.0433.6331.5712.83--
Earnings Per Share-4.27-2.75-2.02-4.17-5.07-2.97-5.1842.504.55
EPS Growth-------834.07%-
Operating Cash Flow-98.64-27.64-10.06-104-124-57.27-46.92-47.93-20.77
Capital Expenditures-45.44-15.53-80.26-1.78-2.72-4.66-0.85-0.19-0.17
Free Cash Flow-144-43.17-90.33-105-127-61.94-47.77-48.12-20.93
Cash & Equivalents6872281912323393151422.730.00
Total Debt31415314598.2291.85-0.054.88-
Net Cash / Debt37374.5746.28133247315142-2.160.00
Assets1,6241,11939226936533315213.07-
Liabilities1,02976823515013934.7515.3631.89-
Book Value594351156120226298137-99.64-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PTC Therapeutics, Inc.
Country United States
Employees 754
CEO Stuart W. Peltz

Stock Information

Ticker Symbol PTCT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PTCT
IPO Date June 20, 2013

Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.